Skip to Content

'
Madeleine Duvic, M.D.

Present Title & Affiliation

Primary Appointment

Deputy Department Chair, Department of Dermatology, Division of Internal Medicine, UTMDACC, Houston, TX
Professor of Medicine and Dermatology (with tenure), Division of Internal Medicine, UTMDACC, Houston, TX
Blanche Bender Professorship in Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, TX
Director of the Research Fellowship Program, Department of Dermatology, Division of Internal Medicine, UTMDACC, Houston, TX

Dual/Joint/Adjunct Appointment

Professor, Division of Epidemiology, Human Genetics & Environmental Sciences, The University of Texas School of Public Health, Houston, TX
Professor of Medicine and Dermatology, The University of Texas Medical School at Houston (UTMSH), Houston, TX

Bio Statement

Madeleine Duvic, M.D., I went to Duke to become a clinician scientist interested in T-cell immunology and in translational research. My goal is to understand the pathogenesis of T-cell mediated skin diseases in order to develop novel targeted therapy. I have collaborated with pharmacology to develop protocols and then conduct clinical trials that lead to the registration of new FDA approved agents for cutaneous T-cell lymphoma that include bexarotene (first rexinoid), denileukin diftitox (first targeted fusion toxin), and vorinostat (first histone deacetylase inhibitor). In addition to directing an NIH funded molecular biology lab and a clinical trials research team, I personally have cared for over 2,000 MD Anderson cutaneous T-cell lymphoma patients. I belong to the UT graduate school immunology program. As a past recipient of a K24 award in cutaneous oncology, I continue to actively mentor research fellows, residents, PhDs, and medical students.

Clinical Interests

   

-     Cutaneous lymphomas and Sezary syndrome

-     Skin cancer and melanoma

Office Address

The University of Texas MD Anderson Cancer Center
1515 Holcombe Blvd.
Unit Number: 1452
Houston, TX 77030
Phone: (713) 745-4615 Clinic (713) 792-6800
Fax: (713) 745-3597

Education & Training

Degree-Granting Education

1977 Duke University Medical School, Durham, NC, MD, Medicine
1973 Rice University, Houston, TX, BA, Biology

Postgraduate Training

8/1984-6/1985 Research Visiting Fellow, Molecular Genetics, Baylor College of Medicine, Houston, TX, Dr. Thomas Caskey
7/1982-7/1984 Postdoctoral Fellowship, Molecular Genetics & Geriatrics, Duke University, Durham, NC, Drs. Russell Kaufman and Sheldon Pinnell
1981-1982 Residency in Internal Medicine, Duke University, Durham, NC
1979 Chief Resident, Dermatology, Duke University, Durham, NC
1978-1980 Residency in Dermatology, Duke University, Durham, NC
1977-1978 Internship in Internal Medicine, Duke University, Durham, NC

Board Certifications

9/1982 American Board of Internal Medicine
6/1981 American Board of Dermatology

Honors and Awards

2001-present America's Top Doctors, Castle Connolly Medical Ltd.
1994-present Best Doctors in America

Selected Publications

Peer-Reviewed Original Research Articles

1. Wang LE, Li C, Xiong P, Gershenwald JE, Prieto VG, Duvic M, Lee JE, Grimm EA, Hsu TC, Wei Q. 4-nitroquinoline-1-oxide-induced mutagen sensitivity and risk of cutaneous melanoma: a case-control analysis. Melanoma Res 26(2):181-7, 4/2016. e-Pub 6/2014. PMID: 24977319.
2. Mudaliar K, Tetzlaff MT, Duvic M, Ciurea A, Hymes S, Milton DR, Tsai KY, Prieto VG, Torres-Cabala CA, Curry JL. BRAF inhibitor therapy-associated melanocytic lesions lack the BRAF V600E mutation and show increased levels of cyclin D1 expression. Hum Pathol 50:79-89, 4/2016. e-Pub 12/2015. PMID: 26997441.
3. Wieser I, Wohlmuth C, Nunez CA, Duvic M. Lymphomatoid Papulosis in Children and Adolescents: A Systematic Review. Am J Clin Dermatol. e-Pub 4/2016. PMID: 27138554.
4. Schlichte MJ, Talpur R, Venkatarajan S, Curry JL, Nagarajan P, Duvic M. Verrucous presentation in patients with mycosis fungoides. Int J Dermatol 55(3):e126-9, 3/2016. e-Pub 10/2015. PMID: 26519087.
5. Oh CW, Ivan D, Curry JL, Ellis R, Gerber H, Duvic M, Torres-Cabala C. A Case of Indeterminate Dendritic Cell Tumor Presenting with Leonine Facies. J Cutan Pathol 43(2):158-63, 2/2016. e-Pub 9/2015. PMID: 26272726.
6. Talpur R, Chockalingam R, Wang C, Tetzlaff MT, Duvic M. A single center experience with Brentuximab Vedotin in gamma delta T-cell lymphoma. Clin Lymphoma Myeloma Leuk 16(2):e15-9, 2/2016. e-Pub 12/2015. PMID: 26705678.
7. Duvic M, Dimopoulos M. The safety profile of vorinostat (suberoylanilide hydroxamic acid) in hematologic malignancies: A review of clinical studies. Cancer Treat Rev 43:58-66, 2/2016. e-Pub 4/2015. PMID: 26827693.
8. Wieser I, Oh CW, Talpur R, Duvic M. Lymphomatoid papulosis: Treatment response and associated lymphomas in a study of 180 patients. J Am Acad Dermatol 74(1):59-67, 1/2016. e-Pub 10/2015. PMID: 26518172.
9. Talpur R, Sui D, Gangar P, Dabaja BS, Duvic M. Retrospective Analysis of Prognostic Factors in 187 Cases of Transformed Mycosis Fungoides. Clin Lymphoma Myeloma Leuk 16(1):49-56, 1/2016. e-Pub 12/2015. PMID: 26702474.
10. Hosing C, Bassett R, Dabaja B, Talpur R, Alousi A, Ciurea S, Popat U, Qazilbash M, Shpall EJ, Oki Y, Nieto Y, Pinnix C, Fanale M, Maadani F, Donato M, Champlin R, Duvic M. Allogeneic Stem Cell Transplantation in Patients With Cutaneous Lymphoma: Updated Results From a Single Institution. Ann Oncol 26(12):2490-5, 12/2015. e-Pub 9/2015. PMID: 26416896.
11. Duvic M. Choosing a systemic treatment for advanced stage cutaneous T-cell lymphoma: mycosis fungoides and Sézary syndrome. Hematology Am Soc Hematol Educ Program 2015(1):529-44, 12/2015. PMID: 26637769.
12. Wang L, Ni X, Covington KR, Yang BY, Shiu J, Zhang X, Xi L, Meng Q, Langridge T, Drummond J, Donehower LA, Doddapaneni H, Muzny DM, Gibbs RA, Wheeler DA, Duvic M. Genomic profiling of Sézary syndrome identifies alterations of key T cell signaling and differentiation genes. Nat Genet 47(12):1426-34, 12/2015. e-Pub 11/2015. PMCID: PMC4829974.
13. Brown DN, Wieser I, Wang C, Dabaja BS, Duvic M. Leonine facies (LF) and mycosis fungoides (MF): A single-center study and systematic review of the literature. J Am Acad Dermatol 73(6):976-86, 12/2015. e-Pub 10/2015. PMID: 26476898.
14. Scarisbrick JJ, Prince HM, Vermeer MH, Quaglino P, Horwitz S, Porcu P, Stadler R, Wood GS, Beylot-Barry M, Pham-Ledard A, Foss F, Girardi M, Bagot M, Michel L, Battistella M, Guitart J, Kuzel TM, Martinez-Escala ME, Estrach T, Papadavid E, Antoniou C, Rigopoulos D, Nikolaou V, Sugaya M, Miyagaki T, Gniadecki R, Sanches JA, Cury-Martins J, Miyashiro D, Servitje O, Muniesa C, Berti E, Onida F, Corti L, Hodak E, Amitay-Laish I, Ortiz-Romero PL, Rodríguez-Peralto JL, Knobler R, Porkert S, Bauer W, Pimpinelli N, Grandi V, Cowan R, Rook A, Kim E, Pileri A, Patrizi A, Pujol RM, Wong H, Tyler K, Stranzenbach R, Querfeld C, Fava P, Maule M, Willemze R, Evison F, Morris S, Twigger R, Talpur R, Kim J, Ognibene G, Li S, Tavallaee M, Hoppe RT, Duvic M, Whittaker SJ, Kim YH. Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model. J Clin Oncol 33(32):3766-73, 11/2015. e-Pub 10/2015. PMID: 26438120.
15. Duvic M, Tetzlaff MT, Gangar P, Clos AL, Sui D, Talpur R. Results of a phase II trial of Brentuximab Vedotin for CD30+ cutaneous T-cell lymphoma and lymphomatoid papulosis. J Clin Oncol 33(32):3759-65, 11/2015. e-Pub 8/2015. PMID: 26261247.
16. Duvic M. Histone deacetylase inhibitors for cutaneous T cell lymphoma. Dermatol Clin 33(4):757-764, 10/2015. e-Pub 8/2015. PMID: 26433847.
17. Litvinov IV, Tetzlaff MT, Rahme E, Jennings MA, Risser DR, Gangar P, Netchiporouk E, Moreau L, Prieto VG, Sasseville D, Duvic M. Demographic patterns of cutaneous T-cell lymphoma incidence in Texas based on two different cancer registries. Cancer Med 4(9):1440-7, 9/2015. e-Pub 7/2015. PMCID: PMC4567029.
18. Ni X, Langridge T, Duvic M. Depletion of regulatory T cells by targeting CC chemokine receptor type 4 with mogamulizumab. Oncoimmunology 4(7):e1011524, 7/2015. e-Pub 3/2015. PMCID: PMC4485778.
19. Shiue LH, Couturier J, Lewis DE, Wei C, Ni X, Duvic M. The effect of extracorporeal photopheresis alone or in combination therapy on circulating CD4+Foxp3+CD25- T-cells in patients with leukemic cutaneous T-cell lymphoma. Photodermatol Photoimmunol Photomed 31(4):184-94, 7/2015. e-Pub 3/2015. PMCID: PMC4504772.
20. Alberti-Violetti S, Talpur R, Schlichte M, Sui D, Duvic M. Advanced-Stage Mycosis Fungoides and Sézary Syndrome: Survival and Response to Treatment. Clin Lymphoma Myeloma Leuk 15(6):e105-12, 6/2015. e-Pub 3/2015. PMID: 25817937.
21. Kazmi SM, Pemmaraju N, Patel KP, Cohen PR, Daver N, Tran KM, Ravandi F, Duvic M, Garcia-Manero G, Pierce S, Nazha A, Borthakur G, Kantarjian H, Cortes J. Characteristics of sweet syndrome in patients with acute myeloid leukemia. Clin Lymphoma Myeloma Leuk 15(6):358-63, 6/2015. e-Pub 12/2014. PMCID: PMC4457594.
22. Litvinov IV, Tetzlaff MT, Rahme E, Habel Y, Risser DR, Gangar P, Jennings MA, Pehr K, Prieto VG, Sasseville D, Duvic M. Identification of geographic clustering and regions spared by cutaneous T-cell lymphoma in Texas using 2 distinct cancer registries. Cancer 121(12):1993-2003, 6/2015. e-Pub 2/2015. PMCID: PMC4457714.
23. Frankel AE, Woo JH, Ahn C, Foss FM, Duvic M, Neville PH, Neville DM. Resimmune--an anti-CD3ε recombinant immunotoxin induces durable remissions in cutaneous T cell lymphoma patients. Haematologica 100(6):794-800, 6/2015. e-Pub 3/2015. PMCID: PMC4450625.
24. Kim EJ, Kim YH, Rook AH, Lerner A, Duvic M, Reddy S, Robak T, Becker JC, Samtsov A, McCulloch W, Waksman J, Whittaker S. Clinically significant responses achieved with romidepsin across disease compartments in patients with cutaneous T-cell lymphoma. Leuk Lymphoma. e-Pub 5/2015. PMID: 25791237.
25. Polansky M, Talpur R, Daulat S, Hosing C, Dabaja B, Duvic M. Long-Term Complete Responses to Combination Therapies and Allogeneic Stem Cell Transplants in Patients With Sézary Syndrome. Clin Lymphoma Myeloma Leuk 15(5):e83-93, 5/2015. e-Pub 10/2014. PMID: 25458083.
26. de la Garza Bravo MM, Patel KP, Loghavi S, Curry JL, Torres Cabala CA, Cason RC, Gangar P, Prieto VG, Medeiros LJ, Duvic M, Tetzlaff MT. Shared clonality in distinctive lesions of lymphomatoid papulosis and mycosis fungoides occurring in the same patients suggests a common origin. Hum Pathol 46(4):558-69, 4/2015. e-Pub 12/2014. PMID: 25666664.
27. Foss F, Advani R, Duvic M, Hymes KB, Intragumtornchai T, Lekhakula A, Shpilberg O, Lerner A, Belt RJ, Jacobsen ED, Laurent G, Ben-Yehuda D, Beylot-Barry M, Hillen U, Knoblauch P, Bhat G, Chawla S, Allen LF, Pohlman B. A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma. Br J Haematol 168(6):811-9, 3/2015. e-Pub 11/2014. PMID: 25404094.
28. Duvic M, Pinter-Brown LC, Foss FM, Sokol L, Jorgensen JL, Challagundla P, Dwyer KM, Zhang X, Kurman MR, Ballerini R, Liu L, Kim YH. Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma. Blood 125(12):1883-9, 3/2015. e-Pub 1/2015. PMCID: PMC4375715.
29. Hoppe RT, Harrison C, Tavallaee M, Bashey S, Sundram U, Li S, Million L, Dabaja B, Gangar P, Duvic M, Kim YH. Low-dose total skin electron beam therapy as an effective modality to reduce disease burden in patients with mycosis fungoides: Results of a pooled analysis from 3 phase-II clinical trials. J Am Acad Dermatol 72(2):286-92, 2/2015. e-Pub 12/2014. PMID: 25476993.
30. Ni X, Jorgensen JL, Goswami M, Challagundla P, Decker WK, Kim YH, Duvic M. Reduction of Regulatory T cells by Mogamulizumab, a Defucosylated Anti-CC Chemokine Receptor 4 Antibody, in Patients with Aggressive/Refractory Mycosis Fungoides and Sézary Syndrome. Clin Cancer Res 21(2):274-85, 1/2015. e-Pub 11/2014. PMID: 25376389.
31. Kash N, Vin H, Danialan R, Prieto VG, Duvic M. Stenotrophomonas maltophilia with histopathological features mimicking cutaneous gamma/delta T-cell lymphoma. Int J Infect Dis 30C:7-9, 1/2015. e-Pub 11/2014. PMID: 25462188.
32. Herrmann JL, Syklawer E, Tarrillion M, Duvic M, Hughey LC. Concomitant Mycosis Fungoides and Vitiligo: How Mycosis Fungoides May Contribute to Melanocyte Destruction. Dermatology 230(2):143-9, 2015. e-Pub 1/2015. PMID: 25634551.
33. Betz RC, Petukhova L, Ripke S, Huang H, Menelaou A, Redler S, Becker T, Heilmann S, Yamany T, Duvic M, Hordinsky M, Norris D, Price VH, Mackay-Wiggan J, de Jong A, DeStefano GM, Moebus S, Böhm M, Blume-Peytavi U, Wolff H, Lutz G, Kruse R, Bian L, Amos CI, Lee A, Gregersen PK, Blaumeiser B, Altshuler D, Clynes R, de Bakker PI, Nöthen MM, Daly MJ, Christiano AM. Genome-wide meta-analysis in alopecia areata resolves HLA associations and reveals two new susceptibility loci. Nat Commun 6:5966, 2015. e-Pub 1/2015. PMCID: PMC4451186.

Book Chapters

1. Pozadzides J, Duvic M, Pro B. Chapter 9: T-cell lymphomas. In: The MD Anderson Manual of Medical Oncology, 3rd Ed, 3rd. Ed(s) Kantarjian HM, Wolff RA, Koller CA. McGraw-Hill, 2014.
2. Duvic M. Cutaneous T-cell lymphomas: Mycosis fungoides and Sezary syndrome. In: Lymphoma: Diagnosis and Treatment. Ed(s) Younes A, Coiffier B. Springer: New York, 287-329, 2013. ISBN: 978-1-62703-407-4.

Books (edited and written)

1. Vahquist A, Duvic M. Ed(s) Taylor & Frances. Retinoids and Carotenoids in Dermatology. Taylor & Frances, 2007.
2. Werth VP, Duvic M. Dermatologic Clinics on Medical Dermatology. WB Saunders, Inc., 2001.

Last updated: 4/28/2016